PTGX - Protagonist Therapeutics, Inc.
Bamco Inc. NY bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,000 shares of the company's stock, valued at approximately $1,961,000. Several other hedge funds have also made changes to
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Small-cap stocks are surging, but how you own them matters more than most investors realize.
Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis and other inflammatory disorders, with phase 2b study initiation planned for Q1 2027.
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Vanguard's tech-heavy portfolio delivered stronger five-year returns despite higher volatility, while Invesco's small-cap approach offers broader sector diversification.
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to a loss of $0.55 per share a year ago.
ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026 Comprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate Early Q1 2027 Phase 1 Study Initiated with PN-477sc, a Triple GLP1/GIP/GCG Agonist Peptide for Obesity Cash, Cash Equivalents and Marketable Securities of $849.5 Million as of June 30, 2026 NEWARK, CA / ACCESS Newswire / August 5, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update. "The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner and accelerating momentum across our internal R&D pipeline.
NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
Bank of New York Mellon Corp lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 341,465 shares of the company's stock after selling 8,923 shares during the quarter. Bank
Fifth Third Bancorp grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 3,937.3% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,202 shares of the company's stock after acquiring an additional 12,875 shares during the period. Fifth
NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.